Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1062-1067

  Amatu, A ^a   Barault, L ^b   Moutinho, C ^c   Cassingena, A ^a   Bencardino, K ^a   Ghezzi, S ^a   Palmeri, L ^a   Bonazzina, E ^a   Tosi, F ^a   Ricotta, R ^a   Cipani, T ^a   Crivori, P ^d   Gatto, R ^d   Chirico, G ^a   Marrapese, G ^a   Truini, M ^a   Bardelli, A ^a,b   Esteller, M ^c   Di Nicolantonio, F ^b,e   Sartore Bianchi, A ^a   Siena, S ^a,f   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d Department of Oncology   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Colorectal cancer; Liquid biopsy; MethylBEAMing; MGMT; Temozolomide

Indexed keywords

B RAF KINASE; BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; REGORAFENIB; TEMOZOLOMIDE; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; CANCER CONTROL; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EPIGENETICS; FEMALE; GENETIC SCREENING; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; KRAS GENE; MALE; METASTATIC COLORECTAL CANCER; MGMT GENE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; TUMOR BIOPSY; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOMARKERS, TUMOR; BIOPSY; COLORECTAL NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84974792549     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw071     Document Type: Article

References (27)

1. Chawla N, Butler E, Lund J et al. Patterns of colorectal cancer care in Europe, Australia, and New Zealand. J Natl Cancer Institute. Monographs 2013; 2013(46): 36-61.
2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014; 136(5): E359-E386.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-345.
5. Amado R, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-1634.
6. Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012; 30(28): 3499-3506.
7. Grothey A, Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863): 303-312.
8. Douillard J-Y, Oliner K, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369(11): 1023-1034.
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343(19): 1350-1354.
10. Esteller M, Herman J. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23(1): 1-8.
11. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60(9): 2368-2371.
12. Ju H, An B, Okamoto Y, et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol 2011; 178(4): 1835-1846.
13. Amatu A, Sartore-Bianchi A, Moutinho C, et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013; 19(8): 2265-2272.
14. Von Hoff D, Stephenson J, Rosen P, et al. Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. J Clin Oncol 2010; 28(33): 4877-4883.
15. Pietrantonio F, Perrone F, de Braud F, et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol 2014; 25(2): 404-408.
16. Hochhauser D, Glynne-Jones R, Potter V, et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013; 12(5): 809-818.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 2009; 45(2): 228-247.
18. Walter T, van Brakel B, Vercherat C, et al. O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents. Br J Cancer 2015; 112(3): 523-531.
19. Tuominen R, Jewell R, van den Oord J, et al. MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. Int J Cancer 2015; 136(12): 2844-2853.
20. Yachi K, Watanabe T, Ohta T, et al. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 2008; 33(3): 469-475.
21. Vlassenbroeck I, Califice S, Diserens A-C, et al. Validation of real-time methylationspecific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008; 10(4): 332-337.
22. Brandes A, Franceschi E, Tosoni A, et al. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neurooncology 2010; 12(3): 283-288.
23. Maglio G, Casagrande M, Guardascione M, et al. MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primary tumors. Future Oncol 2015; 11(8): 1201-1209.
24. Konishi K, Watanabe Y, Shen L, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PloS one 2011; 6(11): e27889.
25. Kalmár A, Péterfia B, Hollósi P, et al. Bisulfite-based DNA methylation analysis from recent and archived formalin-fixed, paraffin embedded colorectal tissue samples. Pathol Oncol Res 2015; 21(4): 1149-1156.
26. Kopetz S, Overman MJ, Chen K, et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol (ASCO Annual Meeting Proceedings) 2014; 32(15 suppl): abstr 3509.
27. Barault L, Amatu A, Bleeker FE, et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol 2015; 26(9): 1994-1999.